Cargando…
Soluble Erythropoietin Receptor Contributes to Erythropoietin Resistance in End-Stage Renal Disease
BACKGROUND: Erythropoietin is a growth factor commonly used to manage anemia in patients with chronic kidney disease. A significant clinical challenge is relative resistance to erythropoietin, which leads to use of successively higher erythropoietin doses, failure to achieve target hemoglobin levels...
Autores principales: | Khankin, Eliyahu V., Mutter, Walter P., Tamez, Hector, Yuan, Hai-Tao, Karumanchi, S. Ananth, Thadhani, Ravi |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2821920/ https://www.ncbi.nlm.nih.gov/pubmed/20169072 http://dx.doi.org/10.1371/journal.pone.0009246 |
Ejemplares similares
-
First-Trimester Follistatin-Like-3 Levels in Pregnancies Complicated by Subsequent Gestational Diabetes Mellitus
por: Thadhani, Ravi, et al.
Publicado: (2010) -
Effect of Periodic Transfusion on Erythropoietin Concentration in End Stage Renal Disease
por: Hong, Sae Yong, et al.
Publicado: (1992) -
Erythropoietin and renal protection
por: Baradaran, Azar, et al.
Publicado: (2013) -
Baseline Soluble Anti-erythropoietin Antibody Level Is an Independent Associated Factor for Follow-Up Erythropoietin Demand in Maintenance Dialysis Patients With End-Stage Renal Disease: A Prospective Cohort Study
por: Zhang, Ying, et al.
Publicado: (2020) -
Response of patients with sickle cell anaemia and end-stage renal disease to erythropoietin treatment
por: Zumrutdal, Aysegul
Publicado: (2010)